Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable sn 2 taxane phospholipid prodrug using αvβ3-targeted theranostic nanoparticles

Theranostics

Volumn 4, Issue 6, 2014, Pages 565-578

  Pan, Dipanjan ^a   Schmieder, Anne H ^a   Wang, Kezheng ^a,b   Yang, Xiaoxia ^a   Senpan, Angana ^a   Cui, Grace ^a   Killgore, Kendall ^c   Kim, Benjamin ^a   Allen, John S ^a   Zhang, Huiying ^a   Caruthers, Shelton D ^a   Shen, Baozhong ^b   Wickline, Samuel A ^a   Lanza, Gregory M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Kereos Inc   (United States)

Author keywords

Lipase labile docetaxel prodrug; Nanoparticles; Perfluorocarbon

Indexed keywords

DOCETAXEL; NANOPARTICLE; PACLITAXEL; PERFLUOROCARBON NANOPARTICLE; PHOSPHOLIPASE; PRODRUG; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; BRIDGED COMPOUND; FLUOROCARBON; TAXANE; TAXOID;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MODEL; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME BLOOD LEVEL; EXPERIMENTAL RABBIT; IN VITRO STUDY; IN VIVO STUDY; LIPID MEMBRANE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CLEAVAGE; PROTEIN TARGETING; TUMOR CELL; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RABBIT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BRIDGED COMPOUNDS; CELLS, CULTURED; ENDOTHELIAL CELLS; FLUOROCARBONS; INTEGRIN ALPHAVBETA3; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPASES; PRODRUGS; RABBITS; TAXOIDS;

EID: 84902526081     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7581     Document Type: Article

References (30)

1. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, et al. Randomized phase III study of docetaxel compared with paclitaxel inmetastatic breast cancer. J Clin Oncol. 2005; 23: 5542-51.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. Apolymer-based, paclitaxel-eluting stent in patients with coronary arterydisease. N Engl J Med. 2004; 350: 221-31.
3. Zhang Z, Mei L, Feng SS. Paclitaxel drug delivery systems. Expert Opin DrugDeliv. 2013; 10: 325-40.
4. Zhou HF, Hu G, Wickline SA, Lanza GM, Pham CT. Synergistic effect ofantiangiogenic nanotherapy combined with methotrexate in the treatment ofexperimental inflammatory arthritis. Nanomedicine (Lond). 2010; 5: 1065-74.
5. Lanza GM, Winter PM, Caruthers SD, Hughes MS, Hu G, Schmieder AH, et al. Theragnostics for tumor and plaque angiogenesis with perfluorocarbonnanoemulsions. Angiogenesis. 2010; 13: 189-202.
6. Lanza GM, Caruthers SD, Winter PM, Hughes MS, Schmieder AH, Hu G, et al. Angiogenesis imaging with vascular-constrained particles: the why and how. Eur J Nucl Med Mol Imaging. 2010; 37 Suppl 1: S114-26.
7. Zhou HF, Chan HW, Wickline SA, Lanza GM, Pham CT. Alpha v beta 3-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 2009; 23: 2978-85.
8. Schmieder AH, Caruthers SD, Zhang H, Williams TA, Robertson JD, WicklineSA, et al. Three-dimensional MR mapping of angiogenesis with alpha 5 beta 1(alpha v beta 3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 2008; 22: 4179-89.
9. Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells witha magnetic resonance imaging nanoparticle contrast agent: implications forrational therapy of restenosis. Circulation. 2002; 106: 2842-7.
10. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, et al. Syntheticanalogues of fumagillin that inhibit angiogenesis and suppress tumourgrowth. Nature. 1990; 348: 555-7.
11. Garrett ER, Eble TE. Studies on the stability of fumagillin. I. Photolyticdegradation in alcohol solution. J Am Pharm Assoc Am Pharm Assoc (Baltim). 1954; 43: 385-90.
12. Garrett ER. Studies on the stability of fumagillin. III. Thermal degradation inthe presence and absence of air. J Am Pharm Assoc Am Pharm Assoc (Baltim). 1954; 43: 539-43.
13. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrationsinhibits angiogenesis without affecting cellular microtubule assembly. Anti-Cancer Drugs. 2003; 14: 13-9.
14. Winter PM, Schmieder AH, Caruthers SD, Keene JL, Zhang H, Wickline SA, etal. Minute dosages of alpha v beta 3-targeted fumagillin nanoparticles impairVx-2 tumor angiogenesis and development in rabbits. FASEB J. 2008; 22: 2758-67.
15. Partlow K, Lanza G, Wickline S. Exploiting lipid raft transport with membranetargeted nanoparticles: A strategy for cytosolic drug delivery. Biomaterials 2008; 29: 3367-75.
16. Soman N, Baldwin S, Hu G, Marsh J, Lanza G, Heuser J, et al. Molecularlytargeted nanocarriers deliver the cytolytic peptide melittin specifically totumor cells in mice, reducing tumor growth. J Clin Invest. 2009; 119(c): 2830-42.
17. Jubo Liu, Payam Zahedi, Faquan Zeng, Allen C. Nano-sized assemblies of aPEG-docetaxel conjugate as a formulation strategy for docetaxel. J Pharm Sci. 2008; 97: 3274-90.
18. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, et al. Noninvasive imaging of myocardial angiogenesis followingexperimental myocardial infarction. J Clin Invest. 2004; 113: 1684-91.
19. Pan D, Pramanik M, Senpan A, Allen JS, Zhang H, Wickline SA, et al. Molecular photoacoustic imaging of angiogenesis with integrin-targeted goldnanobeacons. FASEB J. 2011; 25: 875-82.
20. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos. 2002; 30: 438-45.
21. Hendrikx.JJMA, Dubbelman. A-C, Rosing. H, Schinkel. AH, Schellens. JHM, Beijnen. JH. Quantification of docetaxel and its metabolites in human plasmaby liquid chromatography/tandem mass spectrometry. Rapid CommunMass Spectrom. 2013; 27: 1-10.
22. Winter P, Caruthers S, Zhang H, Williams T, Wickline S, Lanza G. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles andatorvastatin in atherosclerosis. J Am Coll Cardiol Img 2008; 1: 624-34.
23. Schmieder AH, Winter PM, Williams TA, Allen JS, Hu G, Zhang H, et al. Molecular MR imaging of neovascular progression in the Vx2 tumor withalpha v beta 3-targeted paramagnetic nanoparticles. Radiology. 2013; 268: 470-80.
24. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using anovel alpha v beta 3-targeted nanoparticle and 1.5 tesla magnetic resonanceimaging. Cancer Res. 2003; 63: 5838-43.
25. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, etal. Molecular MR imaging of melanoma angiogenesis with alpha v beta 3-targeted paramagnetic nanoparticles. Magn Reson Med. 2005; 53: 621-7.
26. Winter P, Neubauer A, Caruthers S, Harris T, Robertson J, Williams T, et al. Endothelial alpha v beta 3-Integrin targeted fumagillin nanoparticles inhibitangiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2103-9.
27. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, HeimW, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin formetastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-42.
28. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lungcancer. N Engl J Med. 2006; 355: 2542-50.
29. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, etal. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cellcarcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-11.
30. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrentglioblastoma. J Clin Oncol. 2009; 27: 4733-40.